ClinicalTrials.gg
CompletedNCT03775642Updated Apr 16, 2020

Debunking Myths About Contraceptive Safety Among Women in Kingston, Jamaica

An interventional study of Intervention video and Control video in Contraception Behavior, sponsored by Ohio State University. Completed at 1 site in Jamaica. Open to female participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-16.

Sponsored by Ohio State University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
Female
01

Study summary

The primary hypothesis is that the intervention video - based on strategies from cognitive psychology - can correct women's misinformation about long-acting reversible contraception (LARC) and result in higher use of LARC. While there are no direct benefits to participants from being in the study, the research could benefit women in general by providing evidence to help prevent unintended pregnancy. Unlike many interventions that are not feasible for scaling up once shown to be effective in changing people's behavior, the proposed intervention has been carefully designed to impose a low burden to clinic staff and require few resources for translating to wider use. Thus, the investigators expect the intervention to have high potential for influencing clinical care and research for addressing the overall goal of reducing unintended pregnancy.

Read the detailed description

The investigators will conduct a randomized trial (RT) of consenting adult women (N=220) to test the effectiveness of the final intervention video.

Participants in the RT will complete the "Enrollment Questionnaire" and then will be randomized to either watch a short video on 1) debiasing about LARC safety (intervention arm; n=110) or 2) vector control (control arm; n=110) (Figure 2). Participants then will have the option of receiving routine contraceptive services that follow standard care. After three months, trained interviewers will contact participants to administer the short "Follow-up Questionnaire" via telephone. To corroborate participant reporting of contraception use during follow-up, the investigators also will extract data on LARC use from participant medical records.

02

Conditions studied

  • Contraception Behavior
03

In context

Contraception Behavior

132 studies on the registry are indexed under Contraception Behavior; 20 are open to participants now.

This study's enrollment of 225 is below the median of 382 across 106 interventional studies indexed under Contraception Behavior.

Browse Contraception Behavior studies →

Lead sponsor

Ohio State University is the lead sponsor of 663 studies on the registry; 148 are open to participants now.

Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • present at the Comprehensive Health Centre;
  • 18-25 years of age; and
  • sexually active (defined as ≥1 penile-vaginal act in past month);

Exclusion criteria

Exclusion Criteria:

  • known to be pregnant;
  • sterilized;
  • breastfeeding;
  • currently using the IUD or implant; or
  • want pregnancy in the next 12 months
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    Intervention video

    The intervention video will employ debiasing strategies to correct women's misinformation about the safety of the IUD and implant safety.

    Behavioral: Intervention video

  • Placebo comparator
    Control video

    The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration.

    Behavioral: Control video

Interventions

  • BehavioralIntervention video

    The intervention video will employ the debiasing strategies. It will avoid directly articulating contraception-related myths, but instead will provide a limited number of alternative explanations related to IUD and implant safety.

  • BehavioralControl video

    The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration

06

What researchers measure

Primary outcomes

  1. Self-reported initiation of LARC (dichotomous variable for either IUD or implant use vs. neither use)

    Based on survey question on use of the IUD (y/n) and implant (y/n)

    Time frame: within 3 months of enrollment

Secondary outcomes

  1. Self-reported belief about IUD safety

    "Do you think the IUD is very safe, mostly safe, mostly unsafe, or very unsafe?" Responses will be coded as 1-4 (in the order presented) and used in a regression model to determine whether the values differ by randomization arm.

    Time frame: 3 months after enrollment

  2. Self-reported belief about implant safety

    "Do you think the implant is very safe, mostly safe, mostly unsafe, or very unsafe?" Responses will be coded as 1-4 (in the order presented) and used in a regression model to determine whether the values differ by randomization arm.

    Time frame: 3 months after enrollment

  3. Self-reported attitudes toward LARC-related bleeding patterns

    "How do you feel about your bleeding pattern?" Response options consist of "very satisfied, satisfied, neutral, unsatisfied, very unsatisfied." Responses will be coded as 1-5 (in the order presented) and used in a regression model to determine whether the values differ by randomization arm

    Time frame: 3 months after enrollment

07

Study locations

1 site
  • Epidemiology Training Unit
    Kingston, Jamaica
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Sep 2019, 9 months.

Of 64 non-industry interventional studies with no phase under Contraception Behavior, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 9 months is below that.

Counting every sponsor, half of 64 studies reached it within 20 months; a quarter within 13 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2018
First posted
Dec 14, 2018
StartActual
Nov 21, 2018
Primary completionActual
Sep 5, 2019
CompletionActual
Sep 5, 2019
Last update
Apr 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03775642
Collaborators
FHI 360, Epidemiology Research and Training Unit of the Jamaica Ministry of Health, The University of The West Indies
Responsible party
Maria F. Gallo, PhD (Associate Professor, Ohio State University) — Principal investigator
First posted
Dec 14, 2018
Start date
Nov 21, 2018
Primary completion
Sep 5, 2019
Completion
Sep 5, 2019
Last update
Apr 16, 2020

Study contacts

Maria F Gallo, PhD
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion